Times are changing. A renewed interest from big pharma in the rare disease landscape has awakened due to large-scale patent expirations, competition from generics & biosimilars, anemic pipelines, escalating clinical trial costs and a global health-care reform. This means that the traditional blockbuster model has become less viable while the revenue-generating potential of orphan drugs has shown to be huge with a greater return on investment than non-orphan drugs. According to EvaluatePharma, the orphan drugs sales will grow at an annual rate of 11% and constitute 19% of the total share of prescription drugs by 2020, totalling 176 billion dollars.
The rare disease landscape is very complex due to the large amount of stakeholders involved. Despite their different interests they have one goal in common: getting an orphan drug approval that will help save or improve lives. But there are many challenges on the road to orphan drug designation:
Flip the pages to see your ecosystem map and what sessions are specially designed for you. Start building your solid relationships right here, right now!
Welcome to the 5th annual Orphan Drugs Summit.
Editorial Content Director, Orphan Drugs Summit
This beautifully preseved building offers a rich sense of history combined with modern conveniences, making the venue an integral part of a memorable conference experience.
More details about the venue will soon be available, along with information about accomodations.
Download the Orphan Drugs Summit 2015 agenda as a PDF- file: Orphan Drugs Summit 2015.pdf
Download the Orphan Drugs Ecosystem Mapping Report 2015 as a PDF file: Orphan Drugs Ecosystem Mapping Report 2015.pdf
Download the Orphan Drugs Ecosystem Mapping Survey Report 2015 as a PDF- file: Journal Orphan Drugs 1st edition.pdf
Thank you for making the 4th edition of the Orphan Drugs Summit the most productive edition to date. Over 100 participants from all stakeholder positions registered for the conference. Delegates engaged with one another and participated in 14 plenary sessions, 6 stream sessions, 6 round table discussions, and 1 interactive panel.
Whilst the key pillars for orphan drug development remained prominent issues, this year we saw a real focus on collaboration. As we move forward it is becoming more apparent that the future of orphan drug development is intertwined with collaborative development. But what format will collaboration take? Will it be an agency and developer structure? Or will we see more complex and holistic approaches, led by various stakeholders including patient organizations?
Whatever combination stakeholders decide to create in regards to collaboration, pricing, reimbursement, market access and clinical development will continue to play a tremendous role. As we move into 2015 we will still assess these pertinent issues and analyze how they impact the orphan drugs landscape.
We invite you to join us, collaborate, network, and learn at the 5th edition of the Orphan Drugs Summit. Orphan Drugs Summit 2015 – Building a collaborative community
"Progressive, thought provoking and innovative, with cooperative networking"
Hoss Dowlat - Pharmabio Consulting
"It was a fruitful stimulating meeting with lots of networking opportunities"
Brigitte Happ - Happ consulting
"Very interesting meeting with relevant topics. Good way of organizing the meeting with different types of sessions"
Suzanna Theut Stehr-Nielsen - PTC Therapeutics Inc
"Extremely well organized, open discussions and overall pleasant"
Sigurdur Johannesson - AHCFE
"Extremely beneficial both from a content as also from a networking perspective"
Thomas Ogorka - OrphanReach
"A great introduction to the rare disease space and regulatory environment in Europe"
Chris Gibson - U. Utah
"Wonderful experience, great attendees, intimate setting, solid content"
Scott Schliebner - PRA
"This conference was informative, and I met many new people in the area of Orphan Drugs"
Bill Lobb - MME
"The conference offered and good and diverse introduction to the challenges with Orphan Drug development"
Kjeld S. Larsen - Zealand Pharma A/S
"A congress that surpassed all of my expectations. I will definitely attend next year!"
Jonathan Morton - Oxford PharmaGenesis
"The meeting mirrors the growth of Orphan Drugs and provides tools for companies"
Anders Waas - TikoMed
"A very well run conference with an excellent mixture of talks and interactions. A pleasure to attend."
Audrey Jamieson - QCTR Ltd
"Nice to talk on equal terms to such a big variety of people from the Industry."
Susanne Rodholm - Zymenex A/S
Download the Orphan Drugs Post Show Report as a PDF file: Orphan Drugs Post Show Report 2014.pdf